Evolution of the Average Target: DiaSorin S.p.A.

Evolution of the Average Target - DiaSorin S.p.A.

Evolution of the Target Price: DiaSorin S.p.A.

Evolution of the Target Price - DiaSorin S.p.A.

Changes in Analyst Recommendations: DiaSorin S.p.A.

6a429c1709a2b45.rrBX4UQFrKRH_-nTNplK460Vhnuh7SJoHcY_fC2UX5E.9PQc0yVi1MkKlJC3BawompV80SvouWtRVYJyTnL9Nt3NxBmoHG2d8z2ZsA~af0ead7acac1225c16d9500508d64e35
08-12 UBS Downgrades DiaSorin to Sell Rating, Cuts PT MT
08-04 Intermonte Upgrades DiaSorin to Outperform, Boosts PT MT
08-02 DiaSorin: Q2 profitability beat and H2 launches reinforce credibility Alphavalue
07-16 MedTech facing a three-front squeeze Alphavalue
07-07 BNP Paribas Downgrades DiaSorin to Underperform, Reduces PT MT
06-25 Kepler Cheuvreux Begins DiaSorin Coverage with Buy Rating MT
06-22 RBC Capital Raises DiaSorin's PT, Reiterates Outperform Rating MT
06-17 Deutsche Bank Downgrades DiaSorin to Sell, Lowers PT MT
06-11 Piper Sandler Begins Diasorin Coverage with Neutral Rating MT
05-21 DiaSorin: Soft start, loaded H2 Alphavalue
05-11 DiaSorin: Tough quarter, but margins beat and guidance stood firm Alphavalue
05-11 Buy-side prevails on MIB; DiaSorin shows strength AN
04-09 UBS Downgrades DiaSorin to Neutral Rating, Cuts PT MT
03-24 Invest Securities Downgrades DiaSorin to Neutral Rating, Cuts PT MT
03-23 DiaSorin: Lackluster 2026 guidance and execution uncertainty spook investors Alphavalue
03-23 Mediobanca Downgrades Diasorin to Neutral Rating, Cuts PT MT
03-23 Equita SIM Downgrades Diasorin to Hold, Cuts PT MT
12-31 AlphaValue/Baader Europe Lowers DiaSorin's PT, Keeps at Buy MT
12-30 AlphaValue/Baader Europe Cuts Diasorin Price Target, Forecasts Amid Challenges to Near-term Earnings MT
12-30 DiaSorin trims outlook amid market headwinds Alphavalue
11-27 Intesa Sanpaolo Upgrades Diasorin to Buy, Cuts PT MT
11-07 Deutsche Bank Downgrades Diasorin to Hold, Cuts PT MT
11-06 DiaSorin share slump after Q3 earnings miss Alphavalue
11-06 Banca Akros Downgrades Diasorin to Accumulate, Cuts PT MT
25-10-31 DiaSorin receives FDA authorization for Covid and influenza detection kit AN

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-5.09%
+15.09%
+10.41%
+23.06%
+43.42%
+7.85%
+16.96%
+1.21%
+25.9%
+12.11%
Average +15.09%
Weighted average by Cap. +17.54%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
77.24EUR
Average target price
73.31EUR
Spread / Average Target
-5.09%
High Price Target
90.00EUR
Spread / Highest target
+16.52%
Low Price Target
55.00EUR
Spread / Lowest Target
-28.79%

Analyst Consensus Detail

Analyst consensus - DiaSorin S.p.A.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - DiaSorin S.p.A.
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - DiaSorin S.p.A.
  1. Stock Market
  2. Stocks
  3. DIA Stock
  4. Consensus DiaSorin S.p.A.